Support

Women and Families Initiative

The HIV Collaborative Fund, a community organization that raises funds to support treatment for people living with HIV/AIDS, and Johnson & Johnson are partnering in a Women and Families initiative, which focuses on HIV/AIDS treatment preparation services for women. These services include advocacy, treatment and adherence education, counseling on stigma and discrimination, skills-building workshops, and direct service delivery in each of the communities served. Thousands of women in communities throughout Sub-Saharan Africa have been reached over the past few years.

ViiV Healthcare's Positive Action on HIV/AIDS

Set up in 1992, Positive Action is ViiV Healthcare's international HIV/AIDS education, care and community support program. It works with community organizations to build capacity to counter the ignorance and stigma surrounding HIV and AIDS through outreach, education and advocacy. In 2009, ViiV Healthcare provided more than GBP 1 million, funding projects in 46 countries across Africa, Asia, Latin America and Eastern Europe.

Tibotec Cost Recovery Distribution Program

Johnson & Johnson's Tibotec subsidiary collaborates with major not-for-profit suppliers to donate and sell Tibozole TM Miconazole MAT to treat oral thrush in AIDS patients in Sub-Saharan Africa.

The World Diabetes Foundation

The World Diabetes Foundation, established by Novo Nordisk in 2002, works to achieve equal access to diabetes care in the developing world.

Tanzanian Training Center for International Health

Skilled human resources are the backbone of any performing healthcare system. Many developing countries, however, face a big shortage of qualified healthcare personnel. The Tanzanian Training Centre for International Health (TTCIH) aims to strengthen the Tanzanian healthcare system through sustainable human resources development.

Takeda Initiative with Global Fund

The Takeda Initiative is an endowment made by Takeda Pharmaceutical, with an annual value of JPY 100,000,000 (approximately USD 1 million). It is designed to support the Global Fund to Fight AIDS, Tuberculosis and Malaria over the period 2010-2019, primarily for the training of health care workers and strengthening of health care systems in Africa. Controlling the spread of the three major infectious diseases is one of the eight targets set by the United Nations Millennium Development Goals (MDGs).

Sikiliza Leo Project, Uganda

Johnson & Johnson, its Tibotec subsidiary and the African Medical Research Foundation help the Ugandan NGO Sikiliza Leo to provide HIV testing, counseling, treatment and care in rural Uganda. Since March 2003, HIV testing and counseling have been offered to 3,586 community members, of whom 559 have tested positive for HIV. A total of 272 persons receive Home Based Care and a first group of 20 are now receiving ARV therapy.

Sanofi-aventis: TB Free & Other Initiatives

In March 2002, sanofi-aventis and the Nelson Mandela Foundation established the TB Free program, a EUR 15 million effort to increase detection and treatment rates for tuberculosis in South Africa. Initially planned to finish in 2007, it has now been extended to 2010. The partnership trains volunteers to encourage patient compliance during the 6-month treatment, using the WHO-recommended DOTS (Directly Observed Therapy Short-Course) strategy.

Sanofi-aventis: Diabetes Prevention

In 2006, sanofi-aventis launched pilot programs to help improve diabetes disease management in developing countries, in conjunction with the NGO Handicap International, Sante Diabete Mali and other local NGOs in Africa, Asia and Latin America. Several projects were set up in 2007 in Burundi, India, Kenya, Madagascar, Nicaragua, Philippines and Thailand. The program aims to help local health care systems to manage the disease better, prevent the onset of complications and so avoid the subsequent need for surgical interventions such as amputation.

Sanofi-aventis Sleeping Sickness Program

Sleeping sickness has reemerged in Africa as a major health threat. In 2001, sanofi-aventis committed USD 25 million over the years 2001-2006 to help the World Health Organization (WHO) to implement a strategy of adequate medicine supplies, disease surveillance and management, plus R&D for new treatments. After five years, WHO and sanofi-aventis' efforts were estimated to have saved 110,000 lives. In 2006, the company renewed its contract with the WHO and expanded it to address several additional 'most neglected diseases' (see separate entry).

Pages